Here's Why Novartis (NVS) Fell More Than Broader Market

29.02.24 00:00 Uhr

Werte in diesem Artikel

86,10 CHF 0,47 CHF 0,55%


1.186,9 PKT -9,2 PKT -0,77%

2.975,3 PKT 0,8 PKT 0,03%

2.143,9 PKT 0,6 PKT 0,03%

7.238,8 PKT -5,1 PKT -0,07%

1.864,8 PKT -16,1 PKT -0,86%

11.379,6 PKT -86,2 PKT -0,75%

1.568,6 PKT -12,2 PKT -0,77%

15.051,3 PKT -76,0 PKT -0,50%

3.359,7 PKT -5,6 PKT -0,17%

4.385,3 PKT 17,0 PKT 0,39%

14.924,8 PKT -75,4 PKT -0,50%

6.611,9 PKT -27,4 PKT -0,41%

Novartis (NVS) ended the recent trading session at $102.22, demonstrating a -0.9% swing from the preceding day's closing price. The stock's change was less than the S&P 500's daily loss of 0.17%. Meanwhile, the Dow experienced a drop of 0.06%, and the technology-dominated Nasdaq saw a decrease of 0.55%.Coming into today, shares of the drugmaker had lost 4.27% in the past month. In that same time, the Medical sector gained 5.93%, while the S&P 500 gained 3.98%.Analysts and investors alike will be keeping a close eye on the performance of Novartis in its upcoming earnings disclosure. The company's earnings per share (EPS) are projected to be $1.71, reflecting no change from the same quarter last year. Our most recent consensus estimate is calling for quarterly revenue of $11.43 billion, down 11.75% from the year-ago period.In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $7.18 per share and a revenue of $47.44 billion, indicating changes of +4.06% and -4.69%, respectively, from the former year.Investors should also take note of any recent adjustments to analyst estimates for Novartis. These recent revisions tend to reflect the evolving nature of short-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the company's business and profitability.Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 1.35% lower. At present, Novartis boasts a Zacks Rank of #3 (Hold).Looking at valuation, Novartis is presently trading at a Forward P/E ratio of 14.38. This denotes a discount relative to the industry's average Forward P/E of 15.11.We can also see that NVS currently has a PEG ratio of 1.6. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. As the market closed yesterday, the Large Cap Pharmaceuticals industry was having an average PEG ratio of 1.69.The Large Cap Pharmaceuticals industry is part of the Medical sector. With its current Zacks Industry Rank of 174, this industry ranks in the bottom 31% of all industries, numbering over 250.The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.Remember to apply to follow these and more stock-moving metrics during the upcoming trading sessions.Zacks Names #1 Semiconductor Stock It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom.With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028.See This Stock Now for Free >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Novartis AG (NVS): Free Stock Analysis ReportTo read this article on click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

Ausgewählte Hebelprodukte auf Novartis

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Novartis


Quelle: Zacks

Nachrichten zu Novartis AG

Analysen zu Novartis AG

10.04.2024Novartis BuyUBS AG
04.04.2024Novartis BuyJefferies & Company Inc.
04.04.2024Novartis BuyUBS AG
03.04.2024Novartis NeutralJP Morgan Chase & Co.
28.03.2024Novartis UnderweightBarclays Capital
10.04.2024Novartis BuyUBS AG
04.04.2024Novartis BuyJefferies & Company Inc.
04.04.2024Novartis BuyUBS AG
22.03.2024Novartis BuyDeutsche Bank AG
07.02.2024Novartis BuyDeutsche Bank AG
03.04.2024Novartis NeutralJP Morgan Chase & Co.
25.03.2024Novartis HoldJoh. Berenberg, Gossler & Co. KG (Berenberg Bank)
07.02.2024Novartis NeutralJP Morgan Chase & Co.
09.01.2024Novartis NeutralJP Morgan Chase & Co.
08.01.2024Novartis NeutralJP Morgan Chase & Co.
28.03.2024Novartis UnderweightBarclays Capital
06.02.2024Novartis UnderweightBarclays Capital
21.12.2023Novartis UnderweightBarclays Capital
29.11.2023Novartis UnderweightBarclays Capital
23.10.2023Novartis UnderweightBarclays Capital

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Novartis AG nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"